Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children

Abstract

HIV-infected children (n = 243), ≥5 to <18 years old, receiving stable antiretroviral therapy, were stratified by immunologic status and randomly assigned to receive intranasal live attenuated

T Cell Responses of HIV-Infected Children after Administration of Inactivated or Live Attenuated Influenza Vaccines

“…This vaccine has been well tolerated and immunogenic in previously immunized HIV-infected children and adults, but its efficacy in this population has not been established. [3][4][5] LAIV is more effective than TIV in healthy children and confers protection against infection with mismatched strains ofinfluenza. 6,7 Serum antibody responses to LAIV, unlike those to TIV, do not correlate with protection against wild-type infection and the mechanism(s) of protection by LAIV is not completely understood.…”

Vaccination in Patients with Rheumatoid Arthritis Receiving Immunotherapies

“…herpes zoster vaccination, in RA patients receiving immunotherapies has to be clarified [7]. Certainly of interest are immunogenicity and safety aspects of live-attenuated nasal influenza vaccines in immuncompromised RA patients, but have been so far only investigated in children with cancer [70,71] and HIVinfected patients [72].…”

Vaccination in HIV-Infected Adults

“…A study of 57 HIV-infected adults vaccinated with LAIV found no adverse safety concerns and did not demonstrate prolonged viral shedding; 23 similar findings were seen in studies of HIV-infected children. 24,25 However, since data on LAIV have been limited, guidelines continue to recommend against its use. HIV patients with mild egg allergies (only hives without other allergic symptoms) may receive IIV per the guidelines, and a vaccine is now available for those with more severe forms of egg allergy (RIV3, Flublok).…”